GILEAD SCIENCES, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
GILEAD SCIENCES, INC. (GILD) had Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value of $9.17 billion as of 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2018-02-27
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $9.17B.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $3.57B.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $53.00M.
- 2017-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $107.00M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value |
|---|---|
| 2017-12-31 | $9.17B 10-K · filed 2018-02-27 |
| 2017-09-30 | $3.57B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $53.00M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $107.00M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $202.00M 10-K · filed 2018-02-27 |
| 2016-09-30 | $212.00M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $143.00M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $74.00M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $63.00M 10-K · filed 2017-02-27 |
| 2015-09-30 | $75.00M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $37.00M 10-Q · filed 2015-08-05 |
| 2014-12-31 | $1.00M 10-K · filed 2016-02-24 |
| 2013-12-31 | $8.24M 10-K · filed 2014-02-25 |
| 2013-09-30 | $14.47M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $11.77M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-25 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-06 |
| 2012-06-30 | $43.87M 10-Q · filed 2012-08-01 |
| 2012-03-31 | $48.17M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $46.95M 10-K · filed 2013-02-27 |
| 2011-09-30 | $126.56M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $72.82M 10-Q · filed 2011-08-05 |
| 2011-03-31 | $70.87M 10-Q · filed 2011-05-09 |
| 2010-12-31 | $70.77M 10-K · filed 2012-02-23 |
| 2009-12-31 | $104.82M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |